Drugs / Kappa CD28 T cells
Kappa CD28 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00881920 | Jul 2009 → Jul 2018 overdue | leukemia, plasma cell myeloma | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kappa CD28 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00881920 ↗ |
| Known as | kappa-CD28 | “These chimeric T cells (kappa-CD28) are an investigational product not approved by the FDA.” NCT00881920 ↗ |
| Known as | κ.CARTs | “treated 16 patients with relapsed or refractory κ+ non-Hodgkin lymphoma/chronic lymphocytic leukemia (NHL/CLL) or multiple myeloma (MM) with autologous T cells genetically...” PMID 27270177 ↗ Jun 2016 |
| Action | Deplete | “T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells.” NCT00881920 ↗ |
| Modality | Cell therapy | “autologous T cells genetically modified to express κ.CAR” PMID 27270177 ↗ Jun 2016 |
| Route | Intravenous | “Patients will be given an injection of cells into the vein through an IV line.” NCT00881920 ↗ |